Welcome to AZTherapies, Inc.

Our current programs for drug development and commercialization have the following focus: (i) to neutralize the amyloid triggers of Alzheimer’s disease (ALZT-OP1), (ii) to facilitate drug regimen dosing and compliance in persons that already experience some memory loss (ALZT-Patch), (iii) and to lessen the impact of potential damage already done by Alzheimer’s disease (ALZT-QoL).

AZTherapies from Kindea Labs on Vimeo.

If you are interested in joining our study please go to https://clinicaltrials.gov/ for more information.